Do you know when Paxlovid should be used to treat COVID-19? Are you aware of the reasons for the mixed results of its phase 2 and phase 3 clinical trial data versus its real-life studies? Do you know what the most significant concern about Paxlovid is for its future application in treating COVID-19? Reputed as…
9 Things You Need to Know About Paxlovid
PREMIERING 2/9 at 7:30PM ET: Aaron Siri (Part 1): Why Are Vaccine Manufacturers the Most Protected Companies in America?
“When we finally had that data, you got a sense of why they didn’t want the public to have it, because it showed that 7.7 percent of the over 10 million V-safe users reported needing medical care after a COVID-19 vaccine.” Aaron Siri, managing partner at Siri & Glimstad, has led several high-profile lawsuits against…
A Deep Dive Into Oral Antiviral Pills for COVID (Part 1)
As the world figures out how to coexist with COVID-19, the introduction of oral pills looks promising, in addition to the treatments of monoclonal antibodies and remdesivir. In this multiple series of articles, we will review three oral antivirals against COVID: Paxlovid developed by Pfizer, molnupiravir developed by Merck, and Azvudine developed by Genuine Biotech…
‘It Doesn’t Make Sense,’ Experts Trying to Explain White Lungs in China
While the official data from China reports mild disease and low mortalities surrounding the latest COVID-19 outbreaks, Chinese social media is awash with reports of “white lung,” a form of pneumonia often seen in moderate to severe disease. Anecdotal accounts of deaths after infections, and overwhelmed hospitals and morgues, have flooded Weibo and Chinese short-form video…
Concerning Reports of White Lungs in China, Experts Weigh In
While the official data from China reports mild disease and low mortalities surrounding the latest COVID-19 outbreaks, Chinese social media is awash with reports of “white lung,” a form of pneumonia often seen in moderate to severe disease. Anecdotal accounts of deaths after infections, and overwhelmed hospitals and morgues, have flooded Weibo and Chinese short-form video…
LIVE NOW: Newsmakers (Jan. 4): Why Can’t House Republicans Agree on a Leader?
Mark Tapscott, Epoch Times congressional correspondent, talks about why House Republicans are not together in their vote for speaker of the House. Mike Davis, president of the Article III Project, also talks about the vote for House speaker. He shares his thoughts on frontrunner Kevin McCarthy. Thomas Hogan, senior research faculty at the American Institute…
Newsmakers (Jan. 4): Why Can’t House Republicans Agree on a Leader?
Mark Tapscott, Epoch Times congressional correspondent, talks about why House Republicans are not together in their vote for speaker of the House. Mike Davis, president of the Article III Project, also talks about the vote for House speaker. He shares his thoughts on frontrunner Kevin McCarthy. Thomas Hogan, senior research faculty at the American Institute…
LIVE 7 PM ET: Newsmakers (Jan. 4): Why Can’t House Republicans Agree on a Leader?
Mark Tapscott, Epoch Times congressional correspondent, talks about why House Republicans are not together in their vote for speaker of the House. Mike Davis, president of the Article III Project, also talks about the vote for House speaker. He shares his thoughts on frontrunner Kevin McCarthy. Thomas Hogan, senior research faculty at the American Institute…
LIVE 7 PM ET: Newsmakers (Dec. 28): Wave of Chinese Communist Party Elites Dying From COVID
Newsmakers welcomes Dr. Sean Lin, Professor of Biomedical Sciences at Fei Tian College and a former U.S. Army Microbiologist, to talk about the wave of COVID deaths hitting Chinese Communist Party elites; Jenna Ellis, Former Senior Adviser and Counsel to President Donald Trump, speaks about the Supreme Court decision to allow Trump’s Title 42 to…
LIVE NOW: Newsmakers (Dec. 28): Wave of Chinese Communist Party Elites Dying From COVID
Newsmakers welcomes Sean Lin, professor of biomedical sciences at Fei Tian College and a former U.S. Army microbiologist, to talk about the wave of COVID deaths hitting Chinese Communist Party elites. Jenna Ellis, former senior adviser and counsel to President Donald Trump, speaks about the Supreme Court decision to allow Trump’s Title 42 to remain…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`